Literature DB >> 33337509

[Chemical exchange saturation transfer (CEST) : Magnetic resonance imaging in diagnostic oncology].

N von Knebel Doeberitz1, S Maksimovic1, L Loi1, D Paech2.   

Abstract

BACKGROUND: Contrast generation by chemical exchange saturation transfer (CEST) is a recently emerging magnetic resonance imaging (MRI) research field with high clinical potential.
METHODS: This review covers the methodological principles and summarizes the clinical experience of CEST imaging studies in diagnostic oncology performed to date. RESULTS AND
CONCLUSION: CEST enables the detection of lowly concentrated metabolites, such as peptides and glucose, through selective saturation of metabolite-bound protons and subsequent magnetization transfer to free water. This technology yields additional information about metabolic activity and the tissue microenvironment without the need for conventional contrast agents or radioactive tracers. Various studies, mainly conducted in patients with neuro-oncolgic diseases, suggest that this technology may aid to assess tumor malignancy as well as therapeutic response prior to and in the first follow-up after intervention. KEY POINTS: CEST-MRI enables the indirect detection of metabolites without radioactive tracers or contrast agents. Clinical experience exists especially in the setting of neuro-oncologic imaging. In oncologic imaging, CEST-MRI may improve assessment of prognosis and therapy response.

Entities:  

Keywords:  Amide proton transfer; Cancer diagnosis; Magnetization transfer; Metabolic imaging; Oncologic imaging

Mesh:

Substances:

Year:  2021        PMID: 33337509     DOI: 10.1007/s00117-020-00786-z

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  69 in total

Review 1.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

Review 2.  Multiparametric MRI for prostate cancer diagnosis: current status and future directions.

Authors:  Armando Stabile; Francesco Giganti; Andrew B Rosenkrantz; Samir S Taneja; Geert Villeirs; Inderbir S Gill; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Nat Rev Urol       Date:  2019-07-17       Impact factor: 14.432

3.  Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.

Authors:  Heber MacMahon; David P Naidich; Jin Mo Goo; Kyung Soo Lee; Ann N C Leung; John R Mayo; Atul C Mehta; Yoshiharu Ohno; Charles A Powell; Mathias Prokop; Geoffrey D Rubin; Cornelia M Schaefer-Prokop; William D Travis; Paul E Van Schil; Alexander A Bankier
Journal:  Radiology       Date:  2017-02-23       Impact factor: 11.105

Review 4.  MRI for breast cancer screening, diagnosis, and treatment.

Authors:  Monica Morrow; Janet Waters; Elizabeth Morris
Journal:  Lancet       Date:  2011-11-19       Impact factor: 79.321

5.  CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.

Authors:  Maria F Paz; Ricard Yaya-Tur; Iñigo Rojas-Marcos; Gaspar Reynes; Marina Pollan; Lucinda Aguirre-Cruz; Jose Luis García-Lopez; Jose Piquer; María-Jose Safont; Carmen Balaña; Montserrat Sanchez-Cespedes; Mercedes García-Villanueva; Leoncio Arribas; Manel Esteller
Journal:  Clin Cancer Res       Date:  2004-08-01       Impact factor: 12.531

Review 6.  Toxicity of MRI and CT contrast agents.

Authors:  Kendra M Hasebroock; Natalie J Serkova
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

Review 7.  PET/CT imaging in cancer: current applications and future directions.

Authors:  Michael D Farwell; Daniel A Pryma; David A Mankoff
Journal:  Cancer       Date:  2014-06-19       Impact factor: 6.860

8.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Authors:  Wolfgang Wick; Patrick Roth; Christian Hartmann; Peter Hau; Makoto Nakamura; Florian Stockhammer; Michael C Sabel; Antje Wick; Susanne Koeppen; Ralf Ketter; Peter Vajkoczy; Ilker Eyupoglu; Rolf Kalff; Torsten Pietsch; Caroline Happold; Norbert Galldiks; Friederike Schmidt-Graf; Michael Bamberg; Guido Reifenberger; Michael Platten; Andreas von Deimling; Christoph Meisner; Benedikt Wiestler; Michael Weller
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

Review 9.  PET/MRI in Oncological Imaging: State of the Art.

Authors:  Usman Bashir; Andrew Mallia; James Stirling; John Joemon; Jane MacKewn; Geoff Charles-Edwards; Vicky Goh; Gary J Cook
Journal:  Diagnostics (Basel)       Date:  2015-07-21

Review 10.  Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.

Authors:  Anastasia Zikou; Chrissa Sioka; George A Alexiou; Andreas Fotopoulos; Spyridon Voulgaris; Maria I Argyropoulou
Journal:  Contrast Media Mol Imaging       Date:  2018-12-02       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.